GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XOMA Corp (NAS:XOMA) » Definitions » Cyclically Adjusted PB Ratio

XOMA (XOMA) Cyclically Adjusted PB Ratio : 8.53 (As of Apr. 29, 2024)


View and export this data going back to 1986. Start your Free Trial

What is XOMA Cyclically Adjusted PB Ratio?

As of today (2024-04-29), XOMA's current share price is $25.41. XOMA's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was $2.98. XOMA's Cyclically Adjusted PB Ratio for today is 8.53.

The historical rank and industry rank for XOMA's Cyclically Adjusted PB Ratio or its related term are showing as below:

XOMA' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 4.51   Med: 12.69   Max: 43.18
Current: 8.54

During the past years, XOMA's highest Cyclically Adjusted PB Ratio was 43.18. The lowest was 4.51. And the median was 12.69.

XOMA's Cyclically Adjusted PB Ratio is ranked worse than
87.05% of 641 companies
in the Biotechnology industry
Industry Median: 1.74 vs XOMA: 8.54

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

XOMA's adjusted book value per share data for the three months ended in Dec. 2023 was $7.714. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $2.98 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


XOMA Cyclically Adjusted PB Ratio Historical Data

The historical data trend for XOMA's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XOMA Cyclically Adjusted PB Ratio Chart

XOMA Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 12.04 35.18 28.76 10.58 6.22

XOMA Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.58 10.42 7.81 5.09 6.22

Competitive Comparison of XOMA's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, XOMA's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XOMA's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XOMA's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where XOMA's Cyclically Adjusted PB Ratio falls into.



XOMA Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

XOMA's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=25.41/2.98
=8.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

XOMA's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, XOMA's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=7.714/129.4194*129.4194
=7.714

Current CPI (Dec. 2023) = 129.4194.

XOMA Quarterly Data

Book Value per Share CPI Adj_Book
201403 0.326 99.695 0.423
201406 -1.415 100.560 -1.821
201409 -3.376 100.428 -4.351
201412 0.535 99.070 0.699
201503 -2.289 99.621 -2.974
201506 -5.304 100.684 -6.818
201509 -4.914 100.392 -6.335
201512 -0.388 99.792 -0.503
201603 -1.251 100.470 -1.611
201606 -3.391 101.688 -4.316
201609 -5.172 101.861 -6.571
201612 -7.721 101.863 -9.810
201703 -4.114 102.862 -5.176
201706 -3.834 103.349 -4.801
201709 0.499 104.136 0.620
201712 0.701 104.011 0.872
201803 0.677 105.290 0.832
201806 0.579 106.317 0.705
201809 0.137 106.507 0.166
201812 2.162 105.998 2.640
201903 2.754 107.251 3.323
201906 2.405 108.070 2.880
201909 2.946 108.329 3.520
201912 4.508 108.420 5.381
202003 4.212 108.902 5.006
202006 3.485 108.767 4.147
202009 3.451 109.815 4.067
202012 7.692 109.897 9.058
202103 7.253 111.754 8.399
202106 10.303 114.631 11.632
202109 9.861 115.734 11.027
202112 12.534 117.630 13.790
202203 12.259 121.301 13.079
202206 11.809 125.017 12.225
202209 11.377 125.227 11.758
202212 10.823 125.222 11.186
202303 9.988 127.348 10.150
202306 9.594 128.729 9.645
202309 9.232 129.860 9.201
202312 7.714 129.419 7.714

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


XOMA  (NAS:XOMA) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


XOMA Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of XOMA's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


XOMA (XOMA) Business Description

Industry
Traded in Other Exchanges
Address
2200 Powell Street, Suite 310, Emeryville, CA, USA, 94608
XOMA Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceutical or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.
Executives
Bradley Sitko officer: Chief Investment Officer C/O XOMA CORPORATION, 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
Owen Hughes director, officer: Interim CEO C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Biotechnology Value Fund L P other: See Explanation of Responses 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Thomas M. Burns officer: Chief Financial Officer 2910 SEVENTH STREET, BERKELEY CA 94710
James R Neal officer: VP Business Development 2910 SEVENTH STREET, BERKELEY CA 94710
Heather L Franklin director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVE E, SEATTLE WA 98102
Natasha Hernday director 932 SOUTHWOOD BLVD, INCLINE VILLAGE NV 89451
Bvf Ii Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf Gp Holdings Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Bvf I Gp Llc 10 percent owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Van Ness W Denman director C/O XOMA LTD, 2910 SEVENTH ST., BERKELEY CA 94710
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Deepshikha Datta officer: Chief Business Officer 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
John Varian director, officer: Director and CEO ARYX THERAPEUTICS,INC., 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Matthew D Perry director, other: See Explanation of Responses ONE SANSOME STREET, 30TH FLOOR, SAN FRANCISCO CA 94104